These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 19043778)
61. Bevacizumab plus irinotecan in recurrent glioblastoma. Chamberlain MC J Clin Oncol; 2008 Feb; 26(6):1012-3; author reply 1013. PubMed ID: 18281677 [No Abstract] [Full Text] [Related]
62. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas. Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M Tumori; 2015; 101(1):41-5. PubMed ID: 25702676 [TBL] [Abstract][Full Text] [Related]
63. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Chamberlain MC Neurology; 2010 Jan; 74(2):181. PubMed ID: 20065257 [No Abstract] [Full Text] [Related]
64. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. Guiu S; Taillibert S; Chinot O; Taillandier L; Honnorat J; Dietrich PY; Maire JP; Guillamo JS; Guiu B; Catry-Thomas I; Capelle F; Thiebaut A; Cartalat-Carel S; Deville C; Fumoleau P; Desjardins A; Xuan KH; Chauffert B Rev Neurol (Paris); 2008; 164(6-7):588-94. PubMed ID: 18565358 [TBL] [Abstract][Full Text] [Related]
65. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. Kreisl TN; Kim L; Moore K; Duic P; Royce C; Stroud I; Garren N; Mackey M; Butman JA; Camphausen K; Park J; Albert PS; Fine HA J Clin Oncol; 2009 Feb; 27(5):740-5. PubMed ID: 19114704 [TBL] [Abstract][Full Text] [Related]
66. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Prados MD; Lamborn K; Yung WK; Jaeckle K; Robins HI; Mehta M; Fine HA; Wen PY; Cloughesy T; Chang S; Nicholas MK; Schiff D; Greenberg H; Junck L; Fink K; Hess K; Kuhn J; Neuro Oncol; 2006 Apr; 8(2):189-93. PubMed ID: 16533878 [TBL] [Abstract][Full Text] [Related]
67. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Raizer JJ; Grimm S; Chamberlain MC; Nicholas MK; Chandler JP; Muro K; Dubner S; Rademaker AW; Renfrow J; Bredel M Cancer; 2010 Nov; 116(22):5297-305. PubMed ID: 20665891 [TBL] [Abstract][Full Text] [Related]
68. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. Fraum TJ; Kreisl TN; Sul J; Fine HA; Iwamoto FM J Neurooncol; 2011 Nov; 105(2):281-9. PubMed ID: 21603965 [TBL] [Abstract][Full Text] [Related]
69. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. Ghiaseddin A; Reardon D; Massey W; Mannerino A; Lipp ES; Herndon JE; McSherry F; Desjardins A; Randazzo D; Friedman HS; Peters KB Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513 [TBL] [Abstract][Full Text] [Related]
70. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Packer RJ; Jakacki R; Horn M; Rood B; Vezina G; MacDonald T; Fisher MJ; Cohen B Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892 [TBL] [Abstract][Full Text] [Related]
71. Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. Farina P; Tabouret E; Lehmann P; Barrie M; Petrirena G; Campello C; Boucard C; Graillon T; Girard N; Chinot O J Neurooncol; 2017 May; 132(3):433-437. PubMed ID: 28265824 [TBL] [Abstract][Full Text] [Related]
72. Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Rajan B; Ross G; Lim CC; Ashley S; Goode D; Traish D; Brada M Eur J Cancer; 1994; 30A(12):1809-15. PubMed ID: 7880611 [TBL] [Abstract][Full Text] [Related]